Skip to main content
. Author manuscript; available in PMC: 2013 Dec 16.
Published in final edited form as: Am J Gastroenterol. 2012 Jun 12;107(9):1388–1398. doi: 10.1038/ajg.2012.137

Table 1.

Baseline Characteristics of Study Subjects

Control PEG IFN P-value
Patient Number 414 420 NA
Nonresponders, % 63.5 62.4 0.891
Breakthrough/Relapsers, % 15.9 15.7
Express,2 % 20.5 21.9
Age 49.6 (6.7) 51.0 (7.3) 0.005
Male, % 72.7 70.5 0.48
Caucasian, % 72.2 71.7 0.86
Body Mass Index 29.8 (5.2) 29.7 (5.3) 0.83
ALT/ULN 2.22 (1.79) 2.10 (1.59) 0.32
Log10 HCV RNA 6.45 (0.50) 6.46 (0.50) 0.93
Genotype 1, % 92.3 95.9 0.02
Ishak Inflammation 7.5 (2.0) 7.6 (2.1) 0.49
Ishak Fibrosis 4.1 (1.3) 4.0 (1.2) 0.58
Ishak Fibrosis 5–6, % 39.4 38.1 0.71

All values represent Means (± SD) unless otherwise indicated.

1

Compares the distribution of all 3 subsets (Nonresponders, Breakthrough/Relapsers and Express patients) between Control and Treated groups.

2

Express patients received full-dose peginterferon/ribavirin therapy outside of the HALT-C Trial prior to enrollment.7